ArticleCureus2025
Immunohistochemical Expression of SGLT2 in Pancreatic Ductal Adenocarcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is an aggressive neoplasm. Sodium-glucose transport protein 2 (SGLT2) is a sodium-dependent glucose transporter involved in glucose reabsorption from the kidney. This provides the energy required for the viability of the cells. In this study, we aim to determine the expression of SGLT2 by immunohistochemistry (IHC) in various histological grades and tumor stages of PDAC. MATERIALS AND
methodsThis retrospective study was conducted in a tertiary care center and included 41 cases of PDAC. The study duration was 18 months. The paraffin blocks were obtained from archives and histopathologically processed. IHC was done using rabbit polyclonal anti-SGLT2 antibody.
resultsMales were more frequently affected (n=34; 82.93%) as compared to females (n=7; 17.07%); 43.9% (n=18) of the cases were aged >50 years; 70.73% (n=29) of the cases were histologically graded as moderately differentiated adenocarcinoma; 73.17% (n=30) of the cases revealed a positive history of impaired glucose tolerance or diabetes mellitus; this was found to be significantly associated with the histological grade of PDAC (p=0.0053); 65.85% (n=27) of the cases were staged as pT2; 58.54% (n=24) of the cases showed a moderate expression of SGLT2, while 9.76% (n=4) of the cases showed a strong expression. A statistically significant association was found between histological grade and SGLT2 immunoexpression (p=0.0001). A significant association was also found between SGLT2 immunoexpression and pT (tumors) stage (p=0.0002).
conclusionSGLT2 immunoexpression is significantly associated with the histological grade and tumor stage of PDAC. Hence, we suggest that SGLT2 inhibition can be a potential therapeutic strategy in moderate to advanced PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.